BRCA2 and prostate carcinoma: In the absence of HR-deficient human prostate cancer cell lines suitable for screening, we chose to model BRCA2 deficiency through Cre-mediated deletion in primary mouse prostate organoids freshly isolated from Brca2fl/fl mice (Brca2-null, deletion of N-terminal exons 3-4) (32, 33).